Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 22954655)

1.

Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.

Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J.

Lancet Infect Dis. 2012 Nov;12(11):837-44. doi: 10.1016/S1473-3099(12)70196-2. Epub 2012 Sep 4.

PMID:
22954655
2.

Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.

Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, Puri M, Wierzba TF, Donner A, Nair GB, Bhattacharya SK, Dhingra MS, Deen JL, Lopez AL, Clemens J.

Clin Infect Dis. 2013 Apr;56(8):1123-31. doi: 10.1093/cid/cit009. Epub 2013 Jan 29.

3.

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.

Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD.

Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Erratum in: Lancet. 2010 Oct 23;376(9750):1392.

PMID:
19819004
4.

Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.

Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, Holmgren J, Clemens JD.

Lancet. 2005 Jul 2-8;366(9479):44-9.

PMID:
15993232
5.

Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.

Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R.

PLoS Negl Trop Dis. 2012;6(10):e1844. doi: 10.1371/journal.pntd.0001844. Epub 2012 Oct 4.

6.

5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.

Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD.

Lancet Infect Dis. 2013 Dec;13(12):1050-6. doi: 10.1016/S1473-3099(13)70273-1. Epub 2013 Oct 18. Erratum in: Lancet Infect Dis. 2013 Dec;13(12):1011.

PMID:
24140390
7.

Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.

Ali M, Emch M, Yunus M, Sack D, Lopez AL, Holmgren J, Clemens J.

Pediatr Infect Dis J. 2008 Jan;27(1):33-7.

PMID:
18162935
8.

Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy.

Hashim R, Khatib AM, Enwere G, Park JK, Reyburn R, Ali M, Chang NY, Kim DR, Ley B, Thriemer K, Lopez AL, Clemens JD, Deen JL, Shin S, Schaetti C, Hutubessy R, Aguado MT, Kieny MP, Sack D, Obaro S, Shaame AJ, Ali SM, Saleh AA, von Seidlein L, Jiddawi MS.

PLoS Negl Trop Dis. 2012;6(7):e1743. doi: 10.1371/journal.pntd.0001743. Epub 2012 Jul 24.

9.

Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity.

Emch M, Ali M, Park JK, Yunus M, Sack DA, Clemens JD.

Int J Epidemiol. 2006 Aug;35(4):1044-50. Epub 2006 May 24.

10.

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.

Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, Hang PV, Rao MR.

Lancet. 1997 Jan 25;349(9047):231-5.

PMID:
9014909
11.

The case for reactive mass oral cholera vaccinations.

Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, Lopez AL, Jiddawi MS, Clemens JD, von Seidlein L.

PLoS Negl Trop Dis. 2011 Jan 25;5(1):e952. doi: 10.1371/journal.pntd.0000952.

12.

Mass vaccination with a two-dose oral cholera vaccine in a refugee camp.

Legros D, Paquet C, Perea W, Marty I, Mugisha NK, Royer H, Neira M, Ivanoff B.

Bull World Health Organ. 1999;77(10):837-42.

13.

The role of vaccine coverage within social networks in cholera vaccine efficacy.

Root ED, Giebultowicz S, Ali M, Yunus M, Emch M.

PLoS One. 2011;6(7):e22971. doi: 10.1371/journal.pone.0022971. Epub 2011 Jul 29.

14.

Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.

Anh DD, Lopez AL, Thiem VD, Grahek SL, Duong TN, Park JK, Kwon HJ, Favorov M, Hien NT, Clemens JD.

PLoS Negl Trop Dis. 2011 Jan 25;5(1):e1006. doi: 10.1371/journal.pntd.0001006.

15.

Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL.

PLoS Negl Trop Dis. 2011 Oct;5(10):e1289. doi: 10.1371/journal.pntd.0001289. Epub 2011 Oct 18.

16.

Effectiveness of mass oral cholera vaccination in Beira, Mozambique.

Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, Ali M, Ansaruzzaman M, Amos J, Macuamule A, Cavailler P, Guerin PJ, Mahoudeau C, Kahozi-Sangwa P, Chaignat CL, Barreto A, Songane FF, Clemens JD.

N Engl J Med. 2005 Feb 24;352(8):757-67.

17.

Spatial and environmental connectivity analysis in a cholera vaccine trial.

Emch M, Ali M, Root ED, Yunus M.

Soc Sci Med. 2009 Feb;68(4):631-7. doi: 10.1016/j.socscimed.2008.11.025. Epub 2009 Jan 8.

18.

Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.

Kar SK, Sah B, Patnaik B, Kim YH, Kerketta AS, Shin S, Rath SB, Ali M, Mogasale V, Khuntia HK, Bhattachan A, You YA, Puri MK, Lopez AL, Maskery B, Nair GB, Clemens JD, Wierzba TF.

PLoS Negl Trop Dis. 2014 Feb 6;8(2):e2629. doi: 10.1371/journal.pntd.0002629. eCollection 2014 Feb.

19.

Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis.

Jeuland M, Cook J, Poulos C, Clemens J, Whittington D; DOMI Cholera Economics Study Group.

Value Health. 2009 Sep;12(6):899-908. doi: 10.1111/j.1524-4733.2009.00562.x.

PMID:
19824189
20.

First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.

Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Dialo AA, Itama C, Serafini M, Legros D, Grais RF.

PLoS Negl Trop Dis. 2013 Oct 17;7(10):e2465. doi: 10.1371/journal.pntd.0002465. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk